Beijing Tongrentang reported a net income of 575.9 million yuan for the first quarter.
The company generated 5.27 billion yuan in revenue.
There have been 22 buys of Beijing Tongrentang stocks so far.
One stock was held without any changes.
There has been one sale of Beijing Tongrentang stocks within the quarter.
A look at Beijing Tongrentang Co A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tongrentang Co A, a company specializing in Chinese traditional medicines and medicinal wines, has received various Smartkarma Smart Scores indicating its overall outlook. With a strong resilience score of 5, the company demonstrates solid stability and sustainability in the face of market challenges. This resilience factor can potentially contribute to Beijing Tongrentang Co A‘s long-term success.
Moreover, the company has scored high in growth, with a score of 4, suggesting promising potential for expansion and development. Combined with a dividend score of 3 and a momentum score of 3, Beijing Tongrentang Co A shows a balanced performance across different factors. While the value score stands at 2, indicating some room for improvement in this area, the overall outlook for Beijing Tongrentang Co A appears optimistic, especially considering its focus on Chinese traditional medicines and its diverse business operations.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
